SavedAdd your journal

Journals / Mucosa / 2023 / Cilt: 6 Sayı: 1

Tildrakizumab for the treatment of exfoliative cheilitis

Eksfolyatif keilit tedavisinde tildrakizumab

Timothy Cowan(University of New South Wales)0000-0003-1212-269X
Nada Abu Alrub(St George Hospital)0000-0003-3082-2876
Anna Wilson(St George Hospital)0000-0001-5596-2109
Mani Makhija(Kossard Dermatopathology)0000-0001-6200-0055
Dedee Murrell(St George Hospital)0000-0003-2971-0199
Journal
Mucosa
Pages
19–21
Publication Date
2023-01-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life.
📊
Key Findings & Data:Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life.
💡
Conclusion & Impact:This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
🔬Design:Editöre Mektup
📍Scope:Comprehensive Sample
⚙️Variables:biyolojik · keilit · tildrakizumab

Abstract

Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.

🔖

Cite This Article

Cowan, T., Alrub, N. A., Wilson, A., Makhija, M., Murrell, D. (2023). Tildrakizumab for the treatment of exfoliative cheilitis. Mucosa, Cilt: 6 Sayı: 1, 19–21. https://doi.org/10.33204/mucosa.1209480

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Cai L, Wei J, Ma D, et al. Predisposition of hypersensitivity in patients with exfoliative cheilitis. J Dent Sci 2022;17:476-81.
  2. Georgakopoulou E, Loumou P, Grigoraki A, Panagiotopoulos A. Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%. Med Oral Patol Oral Cir Bucal 2021;26:e357-e60.
  3. Liu J, Shi L, Wang X, et al. Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: A randomised controlled clinical trial and monitoring blood concentration. J Oral Pathol Med 2021;50:251-9.
  4. Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005;141:1080-2.
  5. Gueutier A, Leducq S, Joly A, Picon L, Vaillant L, Samimi M. Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors. Int J Dermatol 2019;58:e236-e7.
  6. Taxonera C, Alba C, Colmenares M, Olivares D, Rey E. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review. Therap Adv Gastroenterol 2020;27:13.